GEN Exclusives

More »

GEN News Highlights

More »
Nov 12, 2009

Abbott Shells Out $170M for PanGenetics’ Early-Stage Chronic Pain Therapeutic

  • Abbott will pay $170 million up front for global rights to PanGenetics’ Phase I chronic pain treatment, PG110. PanGenetics could also earn up to another $20 million in milestone payments.
     
    PG110 is a fully humanized nerve growth factor (NGF) antibody currently in development for patients with osteoarthritis. If this Phase I trial is successful, Abbott plans to evaluate the compound in a number of other pain states including chronic lower back pain, cancer pain, and diabetic neuropathic pain.

    NGF is released at sites of tissue damage and inflammation and plays a significant role in the transmission of pain signals by the central nervous system. “The goal for treatment of chronic pain continues to be a potent, long-lasting analgesia that is tolerable for patients without the potential for dependence and abuse,” explians John Leonard, M.D., svp, global R&D, Abbott. “NGF blockers have demonstrated the potential to address all of these needs, making them a promising treatment for chronic pain patients.” 

    This new NGF inhibitor complements Abbott's early-stage pipeline of chronic pain candidates, which span multiple mechanisms including vanilloid cellular receptors, cannabinoid receptors, histamine H3 receptors, and ion-channel targets.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?